The Technical Analyst
Indaptus Therapeutics, [INDP]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Indaptus Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.18% $2.52
/ 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.52 mill |
| EPS: | -1.830 |
| P/E: | -1.380 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 8.54 mill |
| Avg Daily Volume: | 0.0867 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.380 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.380 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.570 (-37.71%) $-0.950 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.25 - 2.79 ( +/- 10.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-22 | Linscott Walt Addison | Buy | 75 000 | Stock Option (Right to Buy) |
| 2024-01-22 | Waltzman Roger J. | Buy | 75 000 | Stock Option (Right to Buy) |
| 2024-01-22 | Sassi Nir | Buy | 40 000 | Stock Option (Right to Buy) |
| 2024-01-22 | Meckler Jeffrey A | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-01-22 | Newman Michael James | Buy | 43 250 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 90 transactions |
| Buy: 2 551 706 | Sell: 72 874 |
Forecast:
16:00 - $2.52
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.52
Forecast 2: 16:00 - $2.52
Forecast 3: 16:00 - $2.52
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.52 (-1.18% ) |
| Volume | 0.0270 mill |
| Avg. Vol. | 0.0867 mill |
| % of Avg. Vol | 31.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INDP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
INDP
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 07:30:00 - Press Release
Indaptus Therapeutics Presents Positive Mechanism Of Action Data At The American Association For Cancer Research Annual Meeting
Results indicate decoy platform broadly boosts immune system's ability to fight tumors directly and indirectly results indicate decoy platform broadly boosts immune system's ability to fight tumors directly and indirectly
2024-03-25 08:30:00 - Press Release
Indaptus Therapeutics Previews Positive Mechanism Of Action Data To Be Presented At The American Association For Cancer Research Annual Meeting
Data demonstrates that company's decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses
2024-03-13 07:30:00 - Press Release
Indaptus Therapeutics Reports Fourth Quarter And Year-end 2023 Financial Results And Provides Corporate Update
New york, march 13, 2024 (globe newswire) -- indaptus therapeutics, inc. (nasdaq: indp) (“indaptus” or the “company”) today announced financial results for the fourth quarter and fiscal year ended december 31, 2023 and provided a corporate update.
2024-03-04 07:30:00 - Press Release
Indaptus Therapeutics Announces Positive Results From Second Cohort Of Phase 1 Trial; Company Initiates Multi-dose Cohort
• positive data following completion of second cohort of phase 1 trial of decoy 20 leads independent safety review committee to recommend initiating multi-dosing cohort
2024-02-08 08:00:00 - Press Release
Indaptus Therapeutics Expands Digital Presence With Launch Of Social Media Channels
New york, feb. 08, 2024 (globe newswire) -- indaptus therapeutics, inc. (nasdaq: indp), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. recognizing the importance of engaging with all stakeholders, indaptus will generate content on a variety of digital platforms, including x (formerly known as twitter) and linkedin.
Latest News
2023-09-06 08:05:00 - GlobeNewsWire
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.
2023-04-20 16:05:00 - GlobeNewsWire
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally's) in Las Vegas, NV.
2023-03-22 08:00:00 - GlobeNewsWire
Indaptus Therapeutics to Present at the Investor Summit Conference
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on March 29, 2023.
2023-03-15 08:05:00 - GlobeNewsWire
Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando.
2022-10-18 07:00:00 - GlobeNewsWire
Indaptus Therapeutics to Present at the LD Micro Main Event XV
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV. The conference is being held on October 25 – 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles.
2022-09-06 09:02:00 - GlobeNewsWire
Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference. The conference is being held on September 12 – 14 at the Lotte New York Palace Hotel.
2022-06-09 07:00:00 - GlobeNewsWire
Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City.
2022-06-03 07:00:00 - GlobeNewsWire
Indaptus Therapeutics to Present at Jefferies Healthcare Conference
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET.
2022-05-19 15:52:32 - PennyStocks
Hot Penny Stocks to Watch Right Now? 3 For Your List in May
Here are three penny stocks for your watchlist right now The post Hot Penny Stocks to Watch Right Now? 3 For Your List in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-19 10:22:54 - InvestorPlace
Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?
Indaptus Therapeutics (INDP) stock is soaring higher on Thursday following an update from the U.S. Food and Drug Administration (FDA). The post Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?